The first question I'd like to address you is what does the guidelines say regarding the application of the therapy in current practice?

I think there has been a very important revolution or evolution in the recent years coming from the 2018 guidelines not really endorsing renal denervation and now all major guidelines and a lot of national guidelines or documents really endorse renal denervation for patients with uncontrolled resistant hypertension.

including taking a pharmacotherapy compounds, including a diuretic, with an EGFR of 40 or above, and with an exclusion of secondary hypertension and pseudoresistance.

So it is broadened, but still the evidence I think behind it is wider than that.

So if you see what the guidelines propose as the ideal candidate, is that also in your practice the candidate that you always take for renal denervation?

Could you give us your opinion on that?

Yes, I think it's very important to really see the difference because resistant hypertension is actually not so common.

But there's a lot of patients who have pseudo-resistance.